Clinical Trial: An Open-Label Extension of a Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
Study Status: Enrolling by invitation
Recruit Status: Enrolling by invitation
Study Type: Interventional
Official Title: An Open-Label Extension of a Randomized, Multicenter, Double-Masked, Vehicle-Controlled Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
Brief Summary: This is a safety extension enrolling subjects participating in Study OTX-101-2016-001
Detailed Summary:
Sponsor: Ocular Technologies SARL
Current Primary Outcome: adverse events [ Time Frame: 40 weeks ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Ocular Technologies SARL
Dates:
Date Received: July 24, 2016
Date Started: July 2016
Date Completion: August 2017
Last Updated: July 29, 2016
Last Verified: July 2016